Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM4 | Q14833 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | ADORA3 | P0DMS8 | 8/20 | 0.48 |
| ▸ | TMEM97 | Q5BJF2 | 3/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.48 |
| ▸ | DRD3 | P35462 | 2/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30637139 | 1.00 | GRM4 (0.51) | GRM4NPC1RAB9AADORA3TMEM97 | |
| SCHEMBL29501836 | 1.00 | GRM4 (0.51) | GRM4NPC1RAB9AADORA3TMEM97 | |
| SCHEMBL196377 | 0.99 | GRM4 (0.49) | GRM4NPC1RAB9AADORA3TMEM97 | |
| SCHEMBL196452 | 0.97 | GRM4 (0.47) | GRM4NPC1RAB9AADORA3TMEM97 | |
| SCHEMBL196310 | 0.94 | RXFP1 (0.47) | GRM4NPC1RAB9AADORA3TMEM97 | |
| SCHEMBL197113 | 0.91 | MAPT (0.57) | GRM4RAB9AADORA3MAPTTP53 | |
| SCHEMBL196681 | 0.88 | RXFP1 (0.53) | GRM4NPC1RAB9ARXFP1MAPT | |
| SCHEMBL934924 | 0.88 | IGF1R (0.52) | GRM4NPC1RAB9AADORA3RXFP1 | |
| SCHEMBL196063 | 0.88 | RXFP1 (0.60) | NPC1RAB9AADORA3RXFP1MAPT | |
| SCHEMBL196744 | 0.87 | MAPT (0.58) | NPC1RAB9AADORA3RXFP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2323661-B1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIV LEIDEN (NL) | 2013-04-17 | — | — | EP | claimed |
| JP-2012500255-A | — | — | 2012-01-05 | — | — | JP | claimed |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2011-06-16 | — | — | US | claimed |
| EP-2323661-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | Universiteit Leiden (NL) | 2011-05-25 | — | — | EP | claimed |
| WO-2010020981-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2010-02-25 | — | — | WO | claimed |
| US-9668959-B2 | A3 adenosine receptor ligands for modulation of pigmentation | ORADIN PHARMACEUTICAL LTD. (IL) | 2017-06-06 | — | — | US | disclosed |
| US-20160136079-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | ORADIN PHARMACEUTICAL LTD. (IL) | 2016-05-19 | — | — | US | disclosed |
| US-9199102-B2 | A3 adenosine receptor ligands for modulation of pigmentation | ORADIN PHARMACEUTICAL LTD. (IL) | 2015-12-01 | — | — | US | disclosed |
| EP-2323661-B1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIV LEIDEN (NL) | 2013-04-17 | — | — | EP | disclosed |
| US-20120134945-A1 | A3 ADENOSINE RECEPTOR LIGANDS FOR MODULATION OF PIGMENTATION | ORADIN PHARMACEUTICAL LTD. (IL) | 2012-05-31 | — | — | US | disclosed |
| CN-102123709-A | A3Adenosine receptor allosteric modulators | UNIV LEIDEN | 2011-07-13 | — | — | CN | disclosed |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2011-06-16 | — | — | US | disclosed |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2011-06-16 | — | — | US | disclosed |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2011-06-16 | — | — | US | disclosed |
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2011-06-16 | — | — | US | disclosed |
| EP-2323661-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | Universiteit Leiden (NL) | 2011-05-25 | — | — | EP | disclosed |
| EP-2323661-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | Universiteit Leiden (NL) | 2011-05-25 | — | — | EP | disclosed |
| WO-2010020981-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010020981-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | UNIVERSITEIT LEIDEN (NL) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110144156-A1 | A3 ADENOSINE RECEPTOR ALLOSTERIC MODULATORS | ADORA3, ADORA2A, ADORA1 | GRM4 1954/4885NPC1 2737/4885RAB9A 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.